🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK — grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≤24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months — use filters for patent-cliff planning.

Page 17 of 18

  1. US 7396664

    VEGF-binding fusion proteins and nucleic acids encoding the same

    Expires Mon Jul 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7396918

    IGF-I fusion polypeptides and therapeutic uses thereof

    Expires Mon Jul 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7378095

    Methods of treating type I diabetes by blocking VEGF-mediated activity

    Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7374758

    Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereof

    Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7374757

    Modified chimeric polypeptides with improved pharmacokinetic properties

    Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7365165

    IL-1 antagonist formulations

    Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7361350

    Use of an IL-1 antagonist for treating arthritis

    Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7355018

    Modified IGF1 polypeptides with increased stability and potency

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7354580

    Method of administering and using VEGF inhibitors for the treatment of human cancer

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7354578

    Method of tumor regression with VEGF inhibitors

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7354582

    Use of VEGF antagonists for the treatment of malignant gliomas

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7354581

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7354579

    Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7351411

    Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)

    Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7309483

    Method of treatment using Tie2 ligand2

    Expires Mon Dec 13 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7306799

    Use of VEGF inhibitors for treatment of eye disorders

    Expires Mon Dec 06 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7303747

    Use of VEGF inhibitors for treatment of eye disorders

    Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7303748

    Method of treating eye injury with local administration of a VEGF inhibitor

    Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7303746

    Methods of treating eye disorders with modified chimeric polypeptides

    Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7300654

    Method of treating corneal transplant rejection in high risk keratoplasty patients

    Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7300653

    Method of treating corneal transplant rejection

    Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7285532

    Therapeutic method for treating bone formation diseases

    Expires Mon Oct 18 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7279159

    VEGF inhibitor polypeptides

    Expires Mon Oct 04 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7241739

    Morphogenic protein

    Expires Mon Jul 05 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7119066

    Modified ciliary neurotrophic factor (CNTF)

    Expires Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7087411

    Fusion protein capable of binding VEGF

    Expires Mon Aug 03 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7070959

    Modified chimeric polypeptides with improved pharmacokinetic properties

    Expires Mon Jun 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7063840

    TIE-2 ligands, methods of making and uses thereof

    Expires Mon Jun 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7052695

    Angiopoietins and methods of treating hypertension

    Expires Mon May 25 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7052691

    Methods of treating diabetes by blocking VEGF-mediated activity

    Expires Mon May 25 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7052705

    Anti-angiogenic peptides

    Expires Mon May 25 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7045302

    Expressed ligand-vascular intercellular signaling molecule

    Expires Mon May 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  33. US 7008781

    Method of enhancing the biological activity of ligands

    Expires Mon Mar 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  34. US 6958140

    Methods of imaging and targeting vasculature

    Expires Mon Oct 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  35. US 6933276

    Methods of treating peripheral neuropathies using neurotrophin-3

    Expires Mon Aug 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  36. US 6927044

    IL-1 receptor based cytokine traps

    Expires Mon Aug 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  37. US 6881395

    TIE-2 ligand-4

    Expires Mon Apr 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  38. US 6852838

    Tyrosine kinase receptors and ligands

    Expires Mon Feb 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  39. US 6846908

    DCR-5 bone affecting ligand

    Expires Mon Jan 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  40. US 6846914

    Tie-2 ligand-3

    Expires Mon Jan 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  41. US 6833349

    Methods of treating inflammatory skin diseases

    Expires Mon Dec 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  42. US 6825008

    Expressed ligand—vascular intercellular signalling molecule

    Expires Mon Nov 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  43. US 6811780

    Methods of using cytokine antagonists to treat HIV infection and AIDS

    Expires Mon Oct 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  44. US 6767894

    Use of ciliary neurotrophic factor

    Expires Mon Jul 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  45. US 6680291

    Modified ciliary neurotrophic factor, method of making and methods of use thereof

    Expires Mon Jan 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  46. US 6660499

    DCR5, a BMP-binding protein, and applications thereof

    Expires Mon Dec 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  47. US 6656474

    Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

    Expires Mon Nov 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  48. US 6645484

    Method of blocking blood vessel growth using tie-2 ligand 2

    Expires Mon Nov 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.